Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Background Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved for the
treatment of type 2 diabetes and obesity and elicit robust improvements in glycemic control …

Objective Obesity and its associated comorbidities represent a global health challenge with
a need for well-tolerated, effective, and mechanistically diverse pharmaceutical …

Hypertension is a major risk factor for cardiovascular and renal diseases in the United States
and worldwide. Obesity accounts for much of the risk for primary hypertension through …

The pathogenesis of non-alcoholic fatty liver disease, particularly the mechanisms whereby
a minority of patients develop a more severe phenotype characterised by hepatocellular …

Type 2 diabetes mellitus (T2DM) is a common clinical chronic disease, while its
pathogenesis is still inconclusive. Intestinal flora, the largest micro-ecological system in the …

Abstract Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the
brain, and acts through hormonal and neural pathways to regulate islet function, satiety, and …

Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular
complications, which represent the major cause of mortality. Despite effective treatment of …

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …

The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …